Keywords: UK, NICE, Bayer, Nexavar, Liver cancer,
UK’s NICE again rejects Bayer’s Nexavar for advanced liver cancer, but company can, and will, appeal
Article | 19 November 2009
Following a further appraisal, the UK’s National Institute for Health and Clinical Excellence (NICE) has again decided against recommending the use of German drug major Bayer’s Nexavar (sorafenib) under the National Health Service for advanced hepatocellular carcinoma (HCC) in patient for whom surgery or therapies in the region the cancer arose have failed or are not suitable, essentially because the drug is too expensive.
Nexavar, which has been shown to extend life, including the quality of life, by several months, in the UK costs around £3,000 ($5,000) a month for treatment. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
